Effects of the coronary artery disease associated LPA and 9p21 loci on risk of aortic valve stenosis.

[1]  M. Lathrop,et al.  Association of LPA Variants With Aortic Stenosis: A Large-Scale Study Using Diagnostic and Procedural Codes From Electronic Health Records , 2017, JAMA cardiology.

[2]  G. Abecasis,et al.  Genome-wide analysis yields new loci associating with aortic valve stenosis , 2017, bioRxiv.

[3]  Jeroen J. Bax,et al.  2017 ESC/EACTS Guidelines for the management of valvular heart disease. , 2017, European heart journal.

[4]  Kelvin K. W. Chan,et al.  Association Between Cardiovascular Risk Factors and Aortic Stenosis: The CANHEART Aortic Stenosis Study. , 2017, Journal of the American College of Cardiology.

[5]  B. Prendergast,et al.  A Replicated, Genome-Wide Significant Association of Aortic Stenosis With a Genetic Variant for Lipoprotein(a): Meta-Analysis of Published and Novel Data. , 2017, Circulation.

[6]  B. Nordestgaard,et al.  Estimating the Population Impact of Lp(a) Lowering on the Incidence of Myocardial Infarction and Aortic Stenosis—Brief Report , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[7]  S. Crooke,et al.  Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials , 2016, The Lancet.

[8]  B. Nordestgaard,et al.  PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis. , 2016, The Journal of clinical endocrinology and metabolism.

[9]  D. Gudbjartsson,et al.  Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease , 2016, Nature Genetics.

[10]  Y. Bossé,et al.  Autotaxin Derived From Lipoprotein(a) and Valve Interstitial Cells Promotes Inflammation and Mineralization of the Aortic Valve , 2015, Circulation.

[11]  Jennifer G. Robinson,et al.  PCSK9 Inhibitors and Cardiovascular Events. , 2015, The New England journal of medicine.

[12]  B. Prendergast,et al.  A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial) , 2015, European heart journal cardiovascular Imaging.

[13]  P. Elliott,et al.  UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age , 2015, PLoS medicine.

[14]  M. Enriquez-Sarano,et al.  Haemodynamic and anatomic progression of aortic stenosis , 2015, Heart.

[15]  Vilmundur Gudnason,et al.  Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis. , 2014, JAMA.

[16]  Catherine M. Otto,et al.  Aortic-valve stenosis--from patients at risk to severe valve obstruction. , 2014, The New England journal of medicine.

[17]  A. Bogers,et al.  Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. , 2013, Journal of the American College of Cardiology.

[18]  B. Nordestgaard,et al.  Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. , 2013, Journal of the American College of Cardiology.

[19]  M. Sandhu,et al.  Lipoprotein(a) levels, genotype and incident aortic stenosis: a prospective Mendelian randomization study and replication in a case-control cohort , 2013 .

[20]  A. Morris,et al.  Genetic variants predicting left ventricular hypertrophy in a diabetic population: a Go-DARTS study including meta-analysis , 2013, Cardiovascular Diabetology.

[21]  Kathleen F. Kerr,et al.  Genetic associations with valvular calcification and aortic stenosis. , 2013, The New England journal of medicine.

[22]  Jennifer Taylor,et al.  ESC/EACTS Guidelines on the management of valvular heart disease. , 2012, European heart journal.

[23]  K. J. Grande-Allen,et al.  Calcific Aortic Valve Disease : Not Simply a Degenerative Process A Review and Agenda for Research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group , 2012 .

[24]  C. Lang,et al.  Impact of renin-angiotensin system blockade therapy on outcome in aortic stenosis. , 2011, Journal of the American College of Cardiology.

[25]  Y. Sakata,et al.  Administration of angiotensin-converting enzyme inhibitors is associated with slow progression of mild aortic stenosis in Japanese patients , 2011, Heart and Vessels.

[26]  Alec Vahanian,et al.  Epidemiology of valvular heart disease in the adult , 2011, Nature Reviews Cardiology.

[27]  K. Teo,et al.  Effect of Lipid Lowering With Rosuvastatin on Progression of Aortic Stenosis: Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) Trial , 2010, Circulation.

[28]  R. Collins,et al.  Genetic variants associated with Lp(a) lipoprotein level and coronary disease. , 2009, The New England journal of medicine.

[29]  J. Chambers,et al.  Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. , 2008, The New England journal of medicine.

[30]  Ludwig A Hothorn,et al.  Data Supplement (unedited) at: , 2007 .

[31]  R. Prescott,et al.  A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. , 2005, The New England journal of medicine.

[32]  C. Otto,et al.  Association of Angiotensin-Converting Enzyme With Low-Density Lipoprotein in Aortic Valvular Lesions and in Human Plasma , 2002, Circulation.

[33]  D. Boyle,et al.  The diabetes audit and research in Tayside Scotland (darts) study: electronic record linkage to create a diabetes register , 1997, BMJ.

[34]  Catherine M. Otto,et al.  Clinical Factors Associated With Calcific Aortic Valve Disease , 1997 .

[35]  M. Sabatine,et al.  PCSK9 Inhibitors and Cardiovascular Events. , 2015, The New England journal of medicine.

[36]  D. Levine,et al.  Automated measurement of lipoprotein(a) by immunoturbidimetric analysis , 1992, International journal of clinical & laboratory research.